Oral antiviral treatments for COVID-19 Prescribing information for GPs


Two antiviral medicines, Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir plus ritonavir) were provisionally approved for use in Australia for the treatment of COVID-19 in January 2022, with supply of the medicines commencing in February 2022.

Initially, supply was limited to state and territory health departments, residential aged care facilities (RACFs), and Aboriginal and Torres Strait Islander communities via Aboriginal Controlled Community Health  Organisations

(ACCHOs). The Federal Government allocated Lagevrio for pre-placement in all RACFs across Australia. States and territories and ACCHOs will be allocated both Paxlovid and Lagevrio.

Both Lagevrio and Paxlovid are now listed on the Pharmaceutical Benefits Scheme (PBS) as Authority Required (Streamlined) items, enabling eligible patients to access these medicines from their local pharmacy where available. 

Regardless of how they are accessed, both medicines require a prescription from a GP, physician or nurse practitioner who meets the prescribing requirements before they can be issued.

The National COVID-19 Clinical Evidence Taskforce (the Taskforce) has released treatment recommendations for the use of both medicines for people aged 18 years or older with confirmed COVID-19 who do not require oxygen and who have one or more risk factors for disease progression. These treatment recommendations are supported by  the Taskforce’s decision tool for drug treatments and risk classification tool (both available on the Taskforce website). Please note that the PBS eligibility for both medicines is broader than the Taskforce recommendations.

Both medicines can decrease the risk of hospitalisation if taken within five days of symptom onset.

Not everyone who tests positive for COVID-19 will require these medicines, and they will both be of most benefit to people at risk of severe disease. GPs are well placed to make decisions with their patients on the appropriateness of these medicines to treat COVID-19 based on the person’s individual risk for disease progression, medical history, current medicines, age and COVID-19 vaccination status − including time since vaccination. 

A COVID-positive person will not be able to attend in person to collect these medicines. Alternate collection or delivery will need to be arranged.

COVID-positive status can be confirmed via a rapid antigen test (RAT) or polymerase chain reaction (PCR) test. When a positive home RAT result is reported and antiviral treatment is being considered, a medically verified confirmatory RAT must be conducted before commencement of treatment.

Telehealth consultations will be sufficient in many cases to determine if treatment is appropriate, including via normal after-hours medical deputising services. It is recommended medical deputising GPs and nurse practitioners work in partnership with the usual treating GP or physician to determine if treatment is appropriate.

A prescription needs to be issued for the medicine to be administered. When medicines have been pre-placed in RACFs and ACCHOs, the recommendation for recording and dispensing prescriptions is to follow the same process for other orders when medicines that are held in stock are issued (for example, antibiotics). Some RACFs and ACCHOs will do this differently, and how prescriptions are handled, and the medicines allocated, will depend on the local processes in place, and local state or territory requirements.

While clinical information systems (CIS) are being updated to include these medicines, they may not initially appear for prescribing purposes. In the interim you can still prescribe the medicines in your CIS by creating a custom medicine entry. It is important to note that the in-built medicine interaction and medical condition checker will not work, and you will need to be aware of the risks and contraindications as outlined in the product information for each medicine, and as per the University of Liverpool’s COVID-19 drug interactions checker.

The two treatments should not be prescribed for the same person at the same time.

Please refer to the prescribing requirements in your state or territory.

As with all medicines, patients or carers will need to provide informed consent for these medicines to be prescribed. GPs working with patients in RACFs may find it helpful to pre-emptively discuss these medicines with their patients, even if they do not have COVID-19, to determine eligibility criteria and obtain pre-consent for these medicines to be prescribed in the event they test positive for COVID-19.

A subsequent discussion is advised at the point at which the patient requires the medicine to confirm the pre-consent is still applicable.

If a patient experiences an adverse event that you think may be related to the prescribed medicine, you can report this directly to the Therapeutic Goods Administration or via your normal state or territory reporting channels.

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log